2456. Immunogenicity and Safety of a MenACWY-CRM Booster Dose 4–6 Years After Primary Quadrivalent Meningococcal Conjugate Vaccination in Healthy US Adolescents and Adults

por Tipton, Mary, Daly, Wendy, Senders, Shelly, Block, Stanley L, Keshavan, Pavitra, Mzolo, Thembile, Pellegrini, Michele
Publicado 2018

1080 Antibody Persistence 5 Years After Vaccination at 2 to 10 Years of Age With Quadrivalent MenACWY-CRM Conjugate Vaccine, And Responses To a Booster Vaccination

por Block, Stanley L., Christensen, Shane, Verma, Bikash, Xie, Fang, Keshavan, Pavitra, Dull, Peter M, Smolenov, Igor
Publicado 2014

Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5–11 Years of Age: A Post Hoc Analysis of a Phase 3 Study

por Baker, Jeffery B., Block, Stanley L., Cagas, Steven E., Macutkiewicz, Laura Burleigh, Collins, Colleen, Sadeghi, Mitra, Sarkar, Sriparna, Williams, Sarah
Publicado 2023

Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children: A Randomized, Double-blind, Active Controlled Phase 3 Safety and Efficacy Trial (miniSTONE-2)

por Baker, Jeffrey, Block, Stanley L., Matharu, Balpreet, Burleigh Macutkiewicz, Laura, Wildum, Steffen, Dimonaco, Sophie, Collinson, Neil, Clinch, Barry, Piedra, Pedro A.
Publicado 2020